Board of Directors
The Evox Board of Directors is comprised of highly accomplished advisors who each contribute significant expertise in their respective fields. They provide support and guidance to the management team of Evox in achieving its bold vision to positively impact human health by creating novel exosome-based biotherapeutics.
Per Lundin, Ph.D.
Chief Executive Officer
Martin Andrews
Chairman
Evan Caplan, M.D.
OrbiMed
Laura Feinleib
Redmile Group
Douglas Treco, Ph.D.
CRISPR Therapeutics
Wallace Wallace
Oxford Science Enterprises
Sarah Gordon Wild
Oxford Nanopore
Per Lundin, Ph.D.
Per Lundin is a serial entrepreneur who serves as Co-Founder & Chief Executive Officer of Evox Therapeutics Ltd. He has ~15 years of experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, which was ultimately acquired in PE-led trade sale. Over the last two decades, Per has been involved in the formation of five biotech companies developing products based on technologies ranging from cell therapies and exosomes to peptide-based drugs and non-viral delivery systems. He currently serves as board director of Breakthrough T1D International and Breakthrough T1D UK, the leading non-profit funder of research to cure, treat and prevent type 1 diabetes. He is a qualified European Patent Attorney with extensive business development and licensing experience; Per earned his Ph.D. from the Karolinska Institute, his M.S. in biotechnology engineering from the Royal Institute of Technology, and his MBA from Stockholm University School of Business.
Martin Andrews
Martin is a respected commercial leader with a strong track record in strategy development and operational delivery most recently as Senior Vice President, Rare Diseases at GlaxoSmithKline, where he oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. He currently serves on the Board of Freeline Therapeutics.
Evan Caplan, M.D.
Evan is a Principal on the private investment team at OrbiMed, a leading healthcare investment firm.
Laura Feinleib
Laura is a Vice President at Redmile Group, specialising in biotechnology venture investing. She brings experience in investment banking, biomedical engineering and optical technology development.
Douglas Treco, Ph.D.
Doug is a seasoned biotech executive with extensive experience founding and leading highly successful biotech companies, including Ra Pharmaceuticals, Inc. (acquired by UCB) and Transkaryotic Therapies Inc. (acquired by Shire Pharmaceuticals). He currently serves as the Lead Independent Director at CRISPR Therapeutics and was most recently Chief Executive Officer and Chairman of Inozyme Pharma (acquired by BioMarin).
Wallace Wallace
Wallace is part of the Independent Investments team at Oxford Science Enterprises, supporting portfolio companies beyond the venture-building phase. She previously invested at M Ventures and began her career in Accenture’s strategy group. Wallace holds a B.Sc. in genetics from the University of York and an MPhil in Bioscience Enterprise from the University of Cambridge.
Sarah Gordon Wild
Sarah has worked on Wall Street for over 15 years and was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She is also currently on the board of Oxford Nanopore and Redx.
Scientific Advisory Board
Michael Benatar, MBChB, M.S., DPhil
University of Miami Miller School of Medicine
Samir El Andaloussi, Ph.D.
Karolinska Institutet
Robert S. Langer, Sc.D.
Massachusetts Institute of Technology
Sarah Tabrizi, M.D., Ph.D., FRS, FMedSci
University College London
Fyodor Urnov, Ph.D.
University of California, Berkeley
Matthew Wood, FMedSci
University of Oxford
Michael Benatar, MBChB, M.S., DPhil
Professor of Neurology and the Walter Bradley Chair in ALS Research at the University of Miami Miller School of Medicine. A trailblazer in pre-symptomatic ALS research, Professor Benatar has led international consortia to discover early biomarkers and develop preventative strategies for amyotrophic lateral sclerosis.
Samir El Andaloussi, Ph.D.
Professor of Biomolecular Medicine and Advanced Therapy at Karolinska Institutet, where he leads the exosome research group within the Department of Laboratory Medicine Karolinska Institutet. A pioneer in extracellular vesicle–based drug delivery, Professor El Andaloussi has characterised exosome biology and engineered novel exosome platforms for macromolecule-based therapies targeting neurodegenerative and neuromuscular diseases.
Robert S. Langer, Sc.D.
Institute Professor in the Departments of Chemical and Biomedical Engineering at MIT, and faculty member of the Harvard–MIT Program in Health Sciences and Technology and the Koch Institute for Integrative Cancer Research. A pioneer in controlled drug delivery, Langer holds over 1,400 patents and has authored over 1,600 papers. He advises Evox on brain and CNS delivery.
Sarah Tabrizi, M.D., Ph.D., FRS, FMedSci
Professor of Neurology at University College London, Director of the UCL Huntington’s Disease Centre, and Group Leader at the UK Dementia Research Institute. Professor Tabrizi spearheaded the first-in-human gene-lowering trials for Huntington’s disease, identifying key biomarkers and translational pathways for neurodegeneration.
Fyodor Urnov, Ph.D.
Professor of Molecular Therapeutics at the University of California, Berkeley, and Director at the Innovative Genomics Institute. A pioneer in genome editing, Professor Urnov co-developed foundational CRISPR/Cas tools and, as a co-founder of the CRISPR Cures centre, helped shepherd the development of a bespoke CRISPR base-editing therapy for “Baby KJ”, the first-ever personalized in vivo gene editing treatment.
Matthew Wood, FMedSci
Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford, and Director of the Laboratory of RNA Biology and Neuromuscular Disease. He launched the field of exosome therapeutics by bioengineering exosomes for RNA delivery in the brain, demonstrating their potential as natural nanocarriers for CNS applications.